Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Diabetes and RA: Further Explanations for Comorbidity

Diabetes and RA: Further Explanations for Comorbidity

  • November 16, 2017
  • Posted in Lab Testing Insights

This post was last updated on December 2, 2019 at 9:41 pm

Doctor speaking with man

Why, how, and what might be next?

By Jason Bhan, MD, Fernando Schwartz, PhD, and Lauren Wiener

If you’ve been following along with us through this series, you know the team at Prognos has been investigating diabetes and rheumatoid arthritis.  Our goal has been to find evidence that diabetes and RA, which are both systemic inflammatory diseases, are also comorbid conditions, while also investigating how this is impacted by disease severity.

In our last blog, we talked you through how our analysis did find evidence of a diabetes and rheumatoid arthritis comorbidity.  Within the Prognos Registry, nearly 30% of patients suffering from RA also suffer from diabetes.  We also found that those RA patients with a double positive diagnosis were actually less likely to also suffer from diabetes.

What This Means

The results of our comorbidity analysis show a strong comorbidity between diabetes and RA, which has yet to be reported with a sample size on this scale. A striking 28.79% of RA patients were found to be diagnosed with diabetes, and 2.51% of diabetes patients were found to have RA. These significant comorbidities could be reflected in standards of care, which would enable physicians to more effectively monitor their diabetes or RA patients for progression of the other disease.

We must admit, it was somewhat surprising to find that a double positive diagnosis was more common in patients who are diagnosed with only RA as compared to comorbid patient with diabetes and RA. Furthermore, our p value was very strong and the observed difference of double positive diagnosis between the two populations is statistically significant. There are a variety of reasons why we may have observed such a difference between a population with only RA and a comorbid population.

One possibility is that this difference is associated with lifestyle choices. It is possible that patients who are more conscious of their health go to the doctor more frequently for tests and monitoring of their RA and are more likely to catch a double positive diagnosis. This health-conscious and doctor compliant population could also be less likely to have diabetes.

Another particularly exciting possibility is that our analysis has uncovered a true independent difference between comorbid and RA only patients. Perhaps diabetes provides some sort of protection against having a double positive RA diagnosis.

What’s Next

The results of our investigation certainly beg the question “what’s next?”.  While we can’t say for sure, our comorbidity results could be reflected in standards of care in the future. Physicians could monitor diabetic patients for progression of RA, which can benefit from early intervention.

If we were to further our investigation, an interesting direction for Prognos to pursue could be to only include patients that are diagnosed with RA by lab tests, and exclude patients diagnosed by only ICD codes. This approach could yield more accurate rates of a double positive diagnosis, and could ameliorate the bias over-reporting non-double positive RA patients.

Another option would be further research and consultation with endocrine and rheumatology specialists to examine the possibility of a physiological relationship between a double positive diagnosis and diabetes. A physiological link may explain why a double positive diagnosis would be less common in a comorbid population than a population of patients with only RA.

Thanks for Reading!

>We appreciate your joining us to explore the comorbidity between diabetes and RA.  As always, we encourage you to follow along with us and to reach out to us with questions or to request additional information.

Reading List

  • https://www.uptodate.com/contents/epidemiology-of-risk-factors-for-and-possible-causes-of-rheumatoid-arthritis?source=search_result&search=rheumatoid%20arthritis%20risk%20factors&selectedTitle=1~150
  • http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/dxc-20197390
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419905/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079714/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145120/
« Comorbidity Between Diabetes and RA
5 ways to optimize sales force efficiency with lab data and AI »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.